You are here

Article Text

Article menu
Download PDFPDF
Uterine Cancer
Management of Leimyosarcoma: A Survey Among Members of the Korean Gynecologic Oncology Group
  1. Mi Kyoung Kim*,
  2. Taek Sang Lee†,
  3. Jae-Weon Kim‡,
  4. Jong-Min Lee§,
  5. Beob Jong Kim∥ and
  6. Seok Ju Seong, MD, PhD*
  1. * Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University, Seoul, Republic of Korea;
  2. † Department of Obstetrics and Gynecology, SMG-SNU Boramae Medical Center, and
  3. ‡ Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea;
  4. § Department of Obstetrics and Gynecology, Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine, Seoul, Republic of Korea; and
  5. ∥ Department of Obstetrics and Gynecology, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea.
  1. Address correspondence and reprint requests to Seok Ju Seong, MD, PhD, Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University, 566, Nonhyeon-ro, Gangnam-gu, Seoul 135-081, Republic of Korea. E-mail: sjseongcheil{at}naver.com.

Abstract

Objective This study aimed to investigate current clinical management of leiomyosarcoma (LMS) in Korea.

Materials and Methods We conducted a Web-based survey among members of the Korean Gynecologic Oncology Group regarding their treatment of LMS.

Results In total, 77 (27.8%) of 277 members responded to the survey. For surgical treatment of stage I LMS, 26.8% indicated total hysterectomy only and 16.9% indicated total hysterectomy with bilateral salpingo-oophorectomy. Also, lymph node dissection was indicated by 54.9% of respondents, whereas 46.5% stated that bilateral salpingo-oophorectomy could be omitted in young patients. More than half (57.7%) of the respondents recommended against adjuvant treatment. For stage I LMS diagnosed after morcellation, 79.2% of the respondents recommended lymph node dissection and 56.4% recommended adjuvant therapy. As for advanced-stage LMS, in cases of complete resection, adjuvant chemotherapy was preferred by 63.1%. For incomplete resection, combined radiotherapy/chemotherapy was the most preferred adjuvant therapy (63.1%).

Conclusions Among Korean Gynecologic Oncology Group members, there are many discrepancies in the clinical management of LMS. A large-scale prospective study to establish treatment guidelines is needed.

  • Uterine leiomyosarcoma
  • Survey
  • Treatment

http://dx.doi.org/10.1097/IGC.0000000000001104

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • The authors declare no conflicts of interest.